Sarepta Therapeutics Inc. stock grades by Barron's. View SRPT fundamental and sentiment analysis powered by MarketGrader.

This afternoon we watched Sarepta Therapeutics rise 5.6% to a price of $58.34 per share. The Mid-Cap Pharmaceutical company is now trading -60.85% below its average target price of $149.0. Analysts ...

PhaseV, a leader in AI/ML-driven clinical development, today announced that the second episode in its webinar series will focus on improving patient-centricity and efficiency in clinical trial design.

Vonage, a global leader in cloud communications helping businesses accelerate their digital transformation and a part of Ericsson , announced that the Company has once again been positioned as a ...

IceCure Medical Ltd. ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor ...

FAIR Health released the second edition of the Monthly Telehealth Regional Tracker Trending Reports, a free set of infographics that show national and regional trends in telehealth from July to ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first ...

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target ...

We recently published a list of the 11 Most Promising Long-Term Stocks According to Analysts. In this article, we are going ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: ...

Biotech stocks climbed Monday after new FDA Commissioner Dr. Marty Makary laid out a clear and collaborative regulatory strategy that analysts say bodes well for drug developers. In his first major ...

Shares of gene therapy companies — including Sarepta Therapeutics — got a lift Monday after FDA's Marty Makary laid out his plans.